Pentraxin-3 in Thrombolytic Therapy for Acute Ischemic Stroke: No Relation with Curative Effect and Prognosis

BACKGROUND Pentraxin-3 (PTX3) is considered a high quality inflammatory marker of the severity and prognosis of several diseases, however, the value of PTX3 in thrombolytic therapy for acute ischemic stroke remains unclear and PTX3 is still controversial in evaluating the prognosis of stroke patient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical science monitor 2018-06, Vol.24, p.4427-4432
Hauptverfasser: Zhang, Chun-Yang, Han, He-Dong, Wang, Si-Yang, Huang, Shi-Ren, Deng, Ben-Qiang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4432
container_issue
container_start_page 4427
container_title Medical science monitor
container_volume 24
creator Zhang, Chun-Yang
Han, He-Dong
Wang, Si-Yang
Huang, Shi-Ren
Deng, Ben-Qiang
description BACKGROUND Pentraxin-3 (PTX3) is considered a high quality inflammatory marker of the severity and prognosis of several diseases, however, the value of PTX3 in thrombolytic therapy for acute ischemic stroke remains unclear and PTX3 is still controversial in evaluating the prognosis of stroke patients. In this study, we investigated the association of PTX3 with thrombolytic therapy in patients with acute ischemic stroke. MATERIAL AND METHODS Forty-seven stroke patients who received thrombolytic therapy within 4.5 hours after symptom onset were enrolled consecutively between July 2016 and June 2017. All the patients underwent multiphase CTA (computerized tomography angiography) or CT perfusion before thrombolysis with no indication for endovascular treatment. Initial and 24 hours of National Institute of Health Stroke Scale (NIHSS) scores and serum PTX3 level, stroke risk factors and predictors, and mRS (modified Rankin scale) at 3 months were collected prospectively. Predictors of thrombolytic therapy effect and long-term prognosis were investigated by univariate and multivariate logistic regression. RESULTS The 24 hour NIHSS score and the treatment time was associated with symptom improvement, while the PTX3 level had no association with neurological improvement and prognosis in stroke patients receiving thrombolytic therapy. CONCLUSIONS PTX3 is not suitable to serve as an indicator of thrombolytic efficacy and had no association with long-term prognosis in stroke patients receiving thrombolytic therapy.
doi_str_mv 10.12659/MSM.909015
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6052828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2061410643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-d4b1f5bc2c13cb27f21d1c717d6ac85bec2b5236174e683057a97b6234a058793</originalsourceid><addsrcrecordid>eNpVUctOwzAQtBCIR-HEHfmIhFL8iPPggFRVPCpRqGg5W47jUEMSF9sB-vdYbangtLua0ezuDACnGPUxSVh-OZ6O-znKEWY74BAnMY1oytDun_4AHDn3hhDJEsT2wQHJ8zhnJD4EzUS13opv3UYU6hbO5tY0hamXXsswKCsWS1gZCwey8wqOnJyrJkBTb827uoKPBj6rWnhtWvil_RwOOxumTwVvqkpJD0Vbwok1r61x2h2DvUrUTp1sag-83N7MhvfRw9PdaDh4iCTNsI_KuMAVKySRmMqCpBXBJZYpTstEyIwVSpKCEZrgNFZJRhFLRZ4WCaGxQCxLc9oD12vdRVc0qpSrH2u-sLoRdsmN0Pw_0uo5fzWfPNhDMpIFgfONgDUfnXKeN9pJVdeiVaZznKAExxgFfwP1Yk2V1jhnVbVdgxFfBcRDQHwdUGCf_b1sy_1NhP4AgDWMnQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2061410643</pqid></control><display><type>article</type><title>Pentraxin-3 in Thrombolytic Therapy for Acute Ischemic Stroke: No Relation with Curative Effect and Prognosis</title><source>Electronic Journals Library</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Zhang, Chun-Yang ; Han, He-Dong ; Wang, Si-Yang ; Huang, Shi-Ren ; Deng, Ben-Qiang</creator><creatorcontrib>Zhang, Chun-Yang ; Han, He-Dong ; Wang, Si-Yang ; Huang, Shi-Ren ; Deng, Ben-Qiang</creatorcontrib><description>BACKGROUND Pentraxin-3 (PTX3) is considered a high quality inflammatory marker of the severity and prognosis of several diseases, however, the value of PTX3 in thrombolytic therapy for acute ischemic stroke remains unclear and PTX3 is still controversial in evaluating the prognosis of stroke patients. In this study, we investigated the association of PTX3 with thrombolytic therapy in patients with acute ischemic stroke. MATERIAL AND METHODS Forty-seven stroke patients who received thrombolytic therapy within 4.5 hours after symptom onset were enrolled consecutively between July 2016 and June 2017. All the patients underwent multiphase CTA (computerized tomography angiography) or CT perfusion before thrombolysis with no indication for endovascular treatment. Initial and 24 hours of National Institute of Health Stroke Scale (NIHSS) scores and serum PTX3 level, stroke risk factors and predictors, and mRS (modified Rankin scale) at 3 months were collected prospectively. Predictors of thrombolytic therapy effect and long-term prognosis were investigated by univariate and multivariate logistic regression. RESULTS The 24 hour NIHSS score and the treatment time was associated with symptom improvement, while the PTX3 level had no association with neurological improvement and prognosis in stroke patients receiving thrombolytic therapy. CONCLUSIONS PTX3 is not suitable to serve as an indicator of thrombolytic efficacy and had no association with long-term prognosis in stroke patients receiving thrombolytic therapy.</description><identifier>ISSN: 1643-3750</identifier><identifier>ISSN: 1234-1010</identifier><identifier>EISSN: 1643-3750</identifier><identifier>DOI: 10.12659/MSM.909015</identifier><identifier>PMID: 29949524</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Clinical Research</subject><ispartof>Medical science monitor, 2018-06, Vol.24, p.4427-4432</ispartof><rights>Med Sci Monit, 2018 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-d4b1f5bc2c13cb27f21d1c717d6ac85bec2b5236174e683057a97b6234a058793</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052828/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052828/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29949524$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Chun-Yang</creatorcontrib><creatorcontrib>Han, He-Dong</creatorcontrib><creatorcontrib>Wang, Si-Yang</creatorcontrib><creatorcontrib>Huang, Shi-Ren</creatorcontrib><creatorcontrib>Deng, Ben-Qiang</creatorcontrib><title>Pentraxin-3 in Thrombolytic Therapy for Acute Ischemic Stroke: No Relation with Curative Effect and Prognosis</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>BACKGROUND Pentraxin-3 (PTX3) is considered a high quality inflammatory marker of the severity and prognosis of several diseases, however, the value of PTX3 in thrombolytic therapy for acute ischemic stroke remains unclear and PTX3 is still controversial in evaluating the prognosis of stroke patients. In this study, we investigated the association of PTX3 with thrombolytic therapy in patients with acute ischemic stroke. MATERIAL AND METHODS Forty-seven stroke patients who received thrombolytic therapy within 4.5 hours after symptom onset were enrolled consecutively between July 2016 and June 2017. All the patients underwent multiphase CTA (computerized tomography angiography) or CT perfusion before thrombolysis with no indication for endovascular treatment. Initial and 24 hours of National Institute of Health Stroke Scale (NIHSS) scores and serum PTX3 level, stroke risk factors and predictors, and mRS (modified Rankin scale) at 3 months were collected prospectively. Predictors of thrombolytic therapy effect and long-term prognosis were investigated by univariate and multivariate logistic regression. RESULTS The 24 hour NIHSS score and the treatment time was associated with symptom improvement, while the PTX3 level had no association with neurological improvement and prognosis in stroke patients receiving thrombolytic therapy. CONCLUSIONS PTX3 is not suitable to serve as an indicator of thrombolytic efficacy and had no association with long-term prognosis in stroke patients receiving thrombolytic therapy.</description><subject>Clinical Research</subject><issn>1643-3750</issn><issn>1234-1010</issn><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVUctOwzAQtBCIR-HEHfmIhFL8iPPggFRVPCpRqGg5W47jUEMSF9sB-vdYbangtLua0ezuDACnGPUxSVh-OZ6O-znKEWY74BAnMY1oytDun_4AHDn3hhDJEsT2wQHJ8zhnJD4EzUS13opv3UYU6hbO5tY0hamXXsswKCsWS1gZCwey8wqOnJyrJkBTb827uoKPBj6rWnhtWvil_RwOOxumTwVvqkpJD0Vbwok1r61x2h2DvUrUTp1sag-83N7MhvfRw9PdaDh4iCTNsI_KuMAVKySRmMqCpBXBJZYpTstEyIwVSpKCEZrgNFZJRhFLRZ4WCaGxQCxLc9oD12vdRVc0qpSrH2u-sLoRdsmN0Pw_0uo5fzWfPNhDMpIFgfONgDUfnXKeN9pJVdeiVaZznKAExxgFfwP1Yk2V1jhnVbVdgxFfBcRDQHwdUGCf_b1sy_1NhP4AgDWMnQ</recordid><startdate>20180627</startdate><enddate>20180627</enddate><creator>Zhang, Chun-Yang</creator><creator>Han, He-Dong</creator><creator>Wang, Si-Yang</creator><creator>Huang, Shi-Ren</creator><creator>Deng, Ben-Qiang</creator><general>International Scientific Literature, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180627</creationdate><title>Pentraxin-3 in Thrombolytic Therapy for Acute Ischemic Stroke: No Relation with Curative Effect and Prognosis</title><author>Zhang, Chun-Yang ; Han, He-Dong ; Wang, Si-Yang ; Huang, Shi-Ren ; Deng, Ben-Qiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-d4b1f5bc2c13cb27f21d1c717d6ac85bec2b5236174e683057a97b6234a058793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Clinical Research</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Chun-Yang</creatorcontrib><creatorcontrib>Han, He-Dong</creatorcontrib><creatorcontrib>Wang, Si-Yang</creatorcontrib><creatorcontrib>Huang, Shi-Ren</creatorcontrib><creatorcontrib>Deng, Ben-Qiang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Chun-Yang</au><au>Han, He-Dong</au><au>Wang, Si-Yang</au><au>Huang, Shi-Ren</au><au>Deng, Ben-Qiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pentraxin-3 in Thrombolytic Therapy for Acute Ischemic Stroke: No Relation with Curative Effect and Prognosis</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2018-06-27</date><risdate>2018</risdate><volume>24</volume><spage>4427</spage><epage>4432</epage><pages>4427-4432</pages><issn>1643-3750</issn><issn>1234-1010</issn><eissn>1643-3750</eissn><abstract>BACKGROUND Pentraxin-3 (PTX3) is considered a high quality inflammatory marker of the severity and prognosis of several diseases, however, the value of PTX3 in thrombolytic therapy for acute ischemic stroke remains unclear and PTX3 is still controversial in evaluating the prognosis of stroke patients. In this study, we investigated the association of PTX3 with thrombolytic therapy in patients with acute ischemic stroke. MATERIAL AND METHODS Forty-seven stroke patients who received thrombolytic therapy within 4.5 hours after symptom onset were enrolled consecutively between July 2016 and June 2017. All the patients underwent multiphase CTA (computerized tomography angiography) or CT perfusion before thrombolysis with no indication for endovascular treatment. Initial and 24 hours of National Institute of Health Stroke Scale (NIHSS) scores and serum PTX3 level, stroke risk factors and predictors, and mRS (modified Rankin scale) at 3 months were collected prospectively. Predictors of thrombolytic therapy effect and long-term prognosis were investigated by univariate and multivariate logistic regression. RESULTS The 24 hour NIHSS score and the treatment time was associated with symptom improvement, while the PTX3 level had no association with neurological improvement and prognosis in stroke patients receiving thrombolytic therapy. CONCLUSIONS PTX3 is not suitable to serve as an indicator of thrombolytic efficacy and had no association with long-term prognosis in stroke patients receiving thrombolytic therapy.</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>29949524</pmid><doi>10.12659/MSM.909015</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1643-3750
ispartof Medical science monitor, 2018-06, Vol.24, p.4427-4432
issn 1643-3750
1234-1010
1643-3750
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6052828
source Electronic Journals Library; PubMed Central Open Access; PubMed Central
subjects Clinical Research
title Pentraxin-3 in Thrombolytic Therapy for Acute Ischemic Stroke: No Relation with Curative Effect and Prognosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T06%3A44%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pentraxin-3%20in%20Thrombolytic%20Therapy%20for%20Acute%20Ischemic%20Stroke:%20No%20Relation%20with%20Curative%20Effect%20and%20Prognosis&rft.jtitle=Medical%20science%20monitor&rft.au=Zhang,%20Chun-Yang&rft.date=2018-06-27&rft.volume=24&rft.spage=4427&rft.epage=4432&rft.pages=4427-4432&rft.issn=1643-3750&rft.eissn=1643-3750&rft_id=info:doi/10.12659/MSM.909015&rft_dat=%3Cproquest_pubme%3E2061410643%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2061410643&rft_id=info:pmid/29949524&rfr_iscdi=true